HEMP 4-U, Aceite CBD + terpenos

Descripción

Modo de uso: Aplicación sublingual. Colocar las gotas debajo de la lengua y dejar allí hasta su completa absorción.

* El efecto obtenido puede variar en función de la sensibilidad de cada persona. Se recomienda empezar con dosis bajas.

HEMP 4-U es un aceite con CBD + terpenos, un producto derivado del cáñamo que sirve como suplemento nutricional de consumo diario. En algunos estudios el cannabidiol (CBD) ha demostrado ser eficaz en tratamientos de: artritis[1], fibromialgia[2],dolores[3], estrés post-traumático[4], ansiedad[5], insomnio[6], tabaquismo[7], dependencia a las benzodiazepinas[8], esquizofrenia[9], epilepsia[10], Parkinson[11], migrañas[12], nauseas[13], hipertensión[14], control de apetito[15], y más.

HEMP 4-U incorpora en su formulación única algunos terpenos provenientes de aceites esenciales para brindarte beneficios y una experiencia inigualable.  Es un producto 100% natural.

HEMP 4-U contiene 1000 mg de CBD  y HEMP 4-U plus contiene 2500 mg de CBD por envase (30 ml).

Ingredientes: Aceite de girasol, extracto concentrado de cáñamo (Cannabis sativa L.), mezcla de aceites esenciales. No contiene THC

Presentación: 30 ml.

Referencias bibliográficas:

[1] Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proceedings of the National Academy of Sciences, 97(17), 9561-9566.

[2] Walitt, B., Klose, P., Fitzcharles, M. A., Phillips, T., & Häuser, W. (2016). Cannabinoids for fibromyalgia. The Cochrane database of systematic reviews, 7(7), CD011694. DOI:10.1002/14651858.CD011694.pub2

[3]Stockings, E., Campbell, G., Hall, W. D., Nielsen, S., Zagic, D., Rahman, R., … & Degenhardt, L. (2018). Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain, 159(10), 1932-1954.

[4] Bitencourt, R. M., & Takahashi, R. N. (2018). Cannabidiol as a therapeutic alternative for post-traumatic stress disorder: From bench research to confirmation in human trials. Frontiers in neuroscience, 12, 502.

[5] Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics, 12(4), 825-836.

[6] Babson, K. A., Sottile, J., & Morabito, D. (2017). Cannabis, cannabinoids, and sleep: a review of the literature. Current psychiatry reports, 19(4), 23.

[7] Morgan, C. J., Das, R. K., Joye, A., Curran, H. V., & Kamboj, S. K. (2013). Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addictive behaviors, 38(9), 2433-2436.

[8] Purcell, C., Davis, A., Moolman, N., & Taylor, S. M. (2019). Reduction of benzodiazepine use in patients prescribed medical cannabis. Cannabis and Cannabinoid Research, 4(3), 214-218.

[9] Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., … & Koethe, D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational psychiatry, 2(3), e94-e94.

[10] Pamplona, F. A., da Silva, L. R., & Coan, A. C. (2018). Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis. Frontiers in neurology, 9, 759.

[11] Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Pinto, J. P., Chagas, M. H. N., Rodrigues, G. G. R., … & Tumas, V. (2009). Cannabidiol for the treatment of psychosis in Parkinson’s disease. Journal of Psychopharmacology, 23(8), 979-983.

[12] Russo, E. B. (2016). Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis and cannabinoid research, 1(1), 154-165.

[13] Parker, L. A., Rock, E. M., & Limebeer, C. L. (2011). Regulation of nausea and vomiting by cannabinoids. British journal of pharmacology, 163(7), 1411-1422.

[14] Jadoon, K. A., Tan, G. D., & O’Sullivan, S. E. (2017). A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI insight, 2(12).

[15] Koch, M. (2017). Cannabinoid receptor signaling in central regulation of feeding behavior: a mini-review. Frontiers in neuroscience, 11, 293.